Literature DB >> 6184313

Interferon effect on cytolytic T lymphocytes in a single cycle assay.

M Bergeret, M Fouchard, A Gregoire, C Chany, D Zagury.   

Abstract

In this study we analyse cell-mediated cytotoxicity by the use of 51chromium release and the killer cell enumeration assay. The latter enabled us to estimate cell-mediated cytotoxicity in a single cycle, which confirms the protective effect of interferon (IFN) after target cell treatment. This anti-cytolytic resistance is detected best by microassociation when effector and target cells are separately treated with IFN and associated thereafter. We suggest that, in inflammatory areas, enhanced cytotoxic activity of the IFN-treated effector cells is only operative before the establishment of protection in the targets, which is somewhat slower and appears in about 18 hr. Resistance of the targets could be at least partly attributed to the incapacity of effector cells to bind to them.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6184313      PMCID: PMC1454018     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  11 in total

1.  Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells.

Authors:  K PAUCKER; K CANTELL; W HENLE
Journal:  Virology       Date:  1962-06       Impact factor: 3.616

2.  Interferon and the interaction of allogeneic normal and immune lymphocytes with L-cells.

Authors:  G J Svet-Moldavsky; I J Chernyakhovskaya
Journal:  Nature       Date:  1967-09-16       Impact factor: 49.962

3.  Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes.

Authors:  P Lindahl; P Leary; I Gresser
Journal:  Proc Natl Acad Sci U S A       Date:  1972-03       Impact factor: 11.205

4.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

Authors:  K T Brunner; J Mauel; J C Cerottini; B Chapuis
Journal:  Immunology       Date:  1968-02       Impact factor: 7.397

5.  Nutritional effects on the polyribosome distribution and rate of protein synthesis in Ehrlich ascites tumor cells in culture.

Authors:  W J Van Ventrooij; E C Henshaw; C A Hirsch
Journal:  J Biol Chem       Date:  1970-11-25       Impact factor: 5.157

6.  Modulation of target cell susceptibility to human natural killer cells by interferon.

Authors:  M Moore; W J White; M R Potter
Journal:  Int J Cancer       Date:  1980-05-15       Impact factor: 7.396

7.  Isoprinosine increases the antitumor action of interferon.

Authors:  I Cerutti; C Chany; J F Schlumberger
Journal:  Int J Immunopharmacol       Date:  1979

8.  Protective effect of interferon on target cells exposed to cellular cytotoxicity.

Authors:  M Bergeret; A Grégoire; C Chany
Journal:  Immunology       Date:  1980-08       Impact factor: 7.397

9.  Regulatory effect of interferon on T cells in vitro.

Authors:  I Heron; K Berg; K Cantell
Journal:  J Immunol       Date:  1976-10       Impact factor: 5.422

10.  Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis.

Authors:  G Trinchieri; D Santoli
Journal:  J Exp Med       Date:  1978-05-01       Impact factor: 14.307

View more
  3 in total

1.  Antitumor therapy based on the use of an immune modulator, arginine butyrate and interferon.

Authors:  C Chany; I Cerutti
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

2.  Coordinated therapeutic effects of immune modulators and interferon.

Authors:  I Cerutti; C Chany
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

3.  Unusual human interferons produced by virus-infected amniotic membranes.

Authors:  P Duc-Goiran; B Robert-Galliot; T Chudzio; C Chany
Journal:  Proc Natl Acad Sci U S A       Date:  1983-05       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.